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Abstract: Approximately 20–30 declared snakebite cases occurin Martinique each year. 
Bothrops lanceolatus, a member of the Crotalidae family, is considered to be the only 
involved snake. B. lanceolatus, commonly named “Fer-de-Lance”, is endemic and only 
found on this Caribbean island. Envenomation local features include the presence of fang 
marks, swelling, pain, bleeding from punctures, and ecchymosis. Severe envenomation is 
associated with multiple systemic thromboses appearing within 48 h of the bite and 
resulting in cerebral, myocardial or pulmonary infarctions. Diagnosis requires first of all 
identification of the snake. Coagulation tests are helpful to identify thrombocytopenia or 
disseminated intravascular coagulation. A clinical score based on 4 grades is helpful to 
assess envonimation severity. A specific monovalent equine anti-venom (Bothrofav
®, 
Sanofi-Pasteur, France) to neutralize B. lanceolatus venom is available. Its early 
administration within 6h from the biting in case of progressive local injures, general signs 
or coagulation disturbances is effective to prevent severe thrombosis and coagulopathy. Its 
tolerance is considered to be good. Despite an increasing incidence of bites, no deaths have 
been recently attributed to B. lanceolatus in Martinique, probably due to the currently 
recommended strategy of early antivenom administration when required. 
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1. Introduction 
Bothrops lanceolatus (Order: Squamata; Suborder: Serpentes; Family: Crotalinae; Figure 1) is 
endemic in Martinique French West Indies. It is commonly called Martinique lancehead (“Fer-de-
Lance”) and Martinican pit viper [1,2]. Each year, approximately 20–30 declared cases of snakebites 
occur in this island [3,4]. B. lanceolatus, which is not found elsewhere in the world, is the only 
indigenous snake present in Martinique. Interestingly, the species was depicted on the unofficial flag 
of Martinique. The reason why it has flourished there and not on the other Caribbean islands has never 
been satisfactorily explained. No B. lanceolatus subspecies are currently recognized. 
Figure 1. Bothrops lanceolatus. 
 
The Island of Martinique is localized in the eastern part of the Caribbean. To the northwest lies 
Dominica and to the south St Lucia. The Martinican population is approximately 402 000 inhabitants 
and live in the 1,128 km
2 island. Martinique is an overseas department of France and a part of the 
European Union. In France, an estimated 3,000 venomous snakebites occur per year. Although B. 
lanceolatus is not found naturally outside of Martinique, it may be imported into zoos, museums, and 
private collections to other regions [3,5]. 
In the past 20 years, the incidence of B. lanceolatus bites has increased in Martinique while its 
mortality rate decreased, probably because of the introduction in 1993 of an effective specific equine 
monovalent antivenom. The purpose of this review is to provide guidelines to help physicians in the 
emergency room and intensive care unit assessing B. lanceolatus envenomation severity and to 
highlight the latest achievements regarding management. 
2. Envonimation Pathophysiology 
Bothrops species snakebites account for the majority of envenomations in South and Central 
America. Envenoming by Bothrops sp. is characterized by a highly complex pathophysiology, 
including local effects like oedema, pain, haemorrhage, and necrosis and systemic effects like 
coagulation disturbances, thrombosis, and renal failure. Bothrops venom generally contains several 
digestive enzymes and spreading factors, resulting in these local and systemic injuries. The major Toxins 2010, 2 
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enzymes are hemorrhagic snake venom zinc-dependent metalloproteinases called “hemorrhagins”, that 
produce haemorrhage by hydrolyzing proteins in the basal lamina of the capillary vessels [6]. Another 
important component is the phospholipase A2, responsible of oedema-formation, myotoxicity, and 
additional anticoagulant effects. 
B. lanceolatus venom induces comparable local and systemic effects with a predominant 
prothrombotic but a rare necrosis and hemorrhage profile. Proteomic studies revealed the following 
content in B. lanceolatus venom: acidic phospholipases A2, serine proteinases, l-amino acid oxidases, 
zinc-dependent metalloproteinases, and a specific C-type lectin-like molecule [7–9]. The 
oedematogenic and hemorrhagic activity of B. lanceolatus venom is thermolabile [10]. Compositional 
differences with other venoms among closely related species from different geographic regions are due 
to evolutionary environmental pressure acting on isolated populations. Although B. lanceolatus venom 
contains approximately the same amount of metalloproteinases than other Bothrops species, its 
metalloproteinase subgroups are different with particular biochemical and pharmacological 
characteristics, like a lesser in vitro gelatinolytic activity [11]. The acidic phospholipase A2 consists in 
two different isoenzymes characterized by a progressive increase in the rate of in vitro hydrolysis 
activity, which seems mainly dependent on the physical state of phospholipids [12]. In mice, B. 
lanceolatus venom produces dose- and time-dependent local oedema and myotoxicity but is devoid of 
coagulant and defibrinogenating effects. The characteristic thrombotic effect described in human 
envenoming is not reproduced in the mouse model. Oedema is partially dependent on a “hemorrhagin” 
and involve the release of arachidonic acid metabolites (by either cyclooxygenase or lipooxygenase), 
bradykinin, histamine, and serotonin [13]. Both polyvalent Crotalinae and monospecific B. 
lanceolatus antivenom were shown to immunodeplete B. lanceolatus venoms in vitro and to be fully 
effective in mice in neutralizing the lethal, hemorrhagic, oedema-forming, myotoxic, and indirect 
hemolytic activities of the venom [7,14,15].  
B. lanceolatus is the only snake in the world whose venom produces significant systemic 
thrombotic complications [2,16]. Development of local thrombosis phenomena is thought to be a result 
of endothelium injury induced by direct action of the venom on the vessels. When added to human-
citrated plasma, the venom of B. lanceolatus has no coagulant effect, even at concentrations as high as 
100 µg/mL [14]. This is a unique feature that characterizes B. lanceolatus venom vis-à-vis other 
Bothrops venoms. Interestingly, the monospecific B. lanceolatus antivenin is devoid of neutralizing 
capacity against the procoagulant and defibrinating activities of heterologous Bothrops snake venoms 
in mice [14]. 
3. Clinical Features 
Envenomation by B. lanceolatus leads to swelling and pain, and occasionally to systemic signs 
and/or coagulopathy. Severity of envenoming by B. lanceolatus depends on the injected amount of 
venom as well as on the victim’s conditions such as age, body weight, immunity, and past medical 
history, as described for other crotalidae bites [17]. The venom isinjected into the subcutaneous tissues 
via hollow movable fangs located in the snake anterior mouth. Occasionally intramuscular and rarely 
intravenous injection may occur.  Toxins 2010, 2 
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Clinically, local effects such as pain, bleeding from the fang punctures, swelling, erythema, 
ecchymoses, and bullae may occur. Local envenomation may increase over time, resulting in serious 
complications such as blistering, local necrosis, abscesses, and extensive swelling involving the whole 
bitten limb and the trunk. Severe envenomation is regularly associated with systemic multifocal 
thrombotic complications, usually occurring within two days after the bite. Rapidly progressive 
swelling is usually indicative of severe envenomation. Hypotension/hypertension, tachycardia, muscle 
fasciculation, weakness, lethargy, difficulty of breathing, chest pain, and (near)-syncope are predictive 
of further life-threatening complications. However, complications may develop in patients who 
initially have signs of only moderate envenomation associated with normal results of blood 
coagulation tests apart from decreased platelet counts [5,18].  
Approximately 30 to 40% of envenomed cases by B. Lanceolatus bites lead to multiple vascular 
obstruction, in which the exact mechanism remains unknown [2]. Vascular thrombosis at distance 
from the site of the bite may occur despite the hypocoagulable conditions due to disseminated 
intravascular coagulation. This is a unique situation in the snake world, closely related B. caribbaeus 
on the neighbouring island of St. Lucia. It differs dramatically from the systemic bothropic syndrome 
observed in Central and South America, characterized by the development of incoagulable blood and 
spontaneous systemic bleeding [2,3]. Thromboses involve cerebral, myocardial, and pulmonary 
arteries, occur despite heparin therapy, and lead to death or major functional sequelae in approximately 
25% of the cases [5,18,19–23]. Of fifty adult snake bite cases hospitalized between June 1991 and 
August 1994 in Fort de France University Hospital, eleven developed serious thrombotic 
complications following envenomation, despite early preventive anticoagulant therapy including 
pulmonary embolism (two cases), cerebral infarction (six cases), myocardial infarction (one case), and 
cerebral and myocardial infarctions (two cases) [5]. Consistently, a 2.6%-prevalence of 
cerebrovascular complications was related to Bothrops spp. bites [21] Intracranial haemorrhages were 
more frequently assessed than cerebral infarcts, in contrast to B. lanceolatus, thus enhancing its 
particularities. Interestingly, a fatal case with diffuse thrombotic microangiopathy causing multiple 
cerebral, myocardial, and mesenteric infarctions at autopsy was reported [24]. Multi-focal thrombotic 
microangiopathy was diagnosed with intimal-medial dissection by thrombi extending from foci of 
endothelial damage in small cerebral, myocardial, pulmonary, mesenteric, and renal arteries and 
arterioles, suggesting the presence inB. Lanceolatus venom of von Willebrand factor activators (like in 
inherited thrombotic thrombocytopenic purpura and hemolytic uremic syndrome) or vascular 
endothelial growth factor-type factors of the kind demonstrated in several Viperidae venoms. 
4. Envenomation Diagnosis 
Diagnosis of B. lanceolatus envenomation is based on the circumstances of the bite and 
identification of the snake, when possible, as well as the presence of bleeding, swelling, and pain from 
the fang punctures (Figure 2). Envenomation severity is assessed using an updated clinical scoring 
(Table 1). On admission, routine laboratory tests are recommended, typically including blood cell 
count, complete coagulation tests (e.g., at least platelets, prothrombin time, activated partial 
thromboplastin time, serum fibrinogen, and clotting factors), and serum chemistry tests (e.g., sodium, Toxins 2010, 2 
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potassium, chloride, bicarbonate, blood urea nitrogen, creatinine, calcium, and phosphorus). Plasma 
creatine phosphokinase is mandatory to rule out rhabdomyolysis.  
Figure 2.  Clinical aspect of Bothrops lanceolatus bite with an extensive inflammatory 
swelling surrounding the fang punctures. 
 
Table 1. Updated severity score after Bothrops lanceolatus bite (evidence of fang marks) 
and subsequent doses ofBothropfav
® antivenom serum to be infused. 
Grade Severity 
a Sy mptoms  Dose of 
antivenom 
b 
1   Minor           No swelling 
No pain 
No general signs 
None 
2  Moderate  Local swelling confined to 2 segments of the bitten limb 
Moderate pain 
No general signs                
40 mL 
3  Severe  Regional oedema: extension of swelling beyond 2 segments 
Persistent and resistant pain to analgesics  
No general signs                
60 mL 
4   Major  Swelling spreading to the trunk 
General signs (vomiting, headache, abdominal or chest pain) 
Hypotension  
Isolated thrombocytopenia  
Disseminated intravascular coagulation 
80 mL 
a  Severity is defined by at least one confirmed item.  
b  To be given by intravenous infusion or by electrical syringe, diluted in isotonic saline with a flow at about 10 to  
20 mL/h. Potential allergic reaction should be considered in all patients. Toxins 2010, 2 
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Coagulopathy commonly occurs with B. lanceolatus envenomation, although clinical bleeding is 
uncommon. Thrombocytopenia most often characterize this coagulopathy, while defibrination is more 
exceptional. Venom-induced thrombocytopenia may exist in association with or independently of 
defibrination. Defibrination is manifested by low serum fibrinogen, elevated prothrombin time, and 
elevated fibrin split products. More than half of the patients envenomed by B. Lanceolatus have 
thrombocytopenia while rare patients develop disseminated intravascular coagulation [5,18,25]. 
Thrombocytopenia, minimally reduced prothrombin, normal activated partial thromboplastin time, and 
elevated fibrinogen concentration are typical features in victims of B. lanceolatus envenomation who 
will further develop thromboses [24]. As no evidence of coagulopathy apart from thrombocytopenia is 
generally observed, thrombosis is thought to result not from a direct procoagulant effect of the venom 
but from a vasculopathic origin (e.g., activation of the vascular endothelium) [1]. The close monitoring 
of platelets count is warranted over the first few days. All patients diagnosed with thrombocytopenia 
have been upgraded to a grade 4 envenoming (Table 1). 
An enzyme-linked immunosorbent assay (ELISA) was developed to measure venom antigen levels 
in the serum of patients bitten by B. lanceolatus [25]. A good correlation was found between blood 
venom levels and clinical indicators of envenomation severitv. Serum venom levels significantly 
increased with the grade of severity. However, venom antigens could not be detected in the serum of 
54% of patients who showed clinical signs of envenomation. No venom was detectable in blood 
samples taken after completion of serotherapy. In contrast, venom concentrations ≥ 15 ng/mL were 
observed in all patients with progressive aggravation of swelling despite the use of early antivenom 
therapy.  
Otherwise, plain radiographs may depict teeth or fangs retained in the wound. Chest X-rays, 
electrocardiography, and serum troponin I-c measurement may be indicated on the basis of 
envenoming severity. When suspecting thrombotic or embolic complications, additional radiological 
examinations may be useful. A head CT-scan and if available, a MRI should be considered in patients 
with headaches or altered level of consciousness if presenting severe thrombopenia or rarely any other 
coagulopathy, to rule out cerebral infarctions or haemorrhages. 
5. Prehospital and Emergency Department Cares 
After a bite fromB. Lanceolatus, the victim should be moved and placed at rest and transported to 
the emergency department of the nearest hospital [26]. The ABC’s (airway, breathing, and circulation) 
should be first addressed. General support of airway, breathing, and circulation should be given per 
advanced cardiac life support (ACLS) protocols with oxygen, two large bore intravenous lines, fluid 
challenge, and close monitoring. Minimizing patient’s activity is recommended when possible. 
Removing jewellery and tight-fitting clothes should be done in anticipation of swelling. After 
stabilization, a rapid detailed history should be obtained with a complete physical examination. The 
bite should be examined carefully to rule out fang, scratches, oedema, erythema, and ecchymoses. A 
pen to mark and time the border of advancing oedema is often enough to gauge progression. 
Subsequently, repeated measurements of the site of the bite should be documented until local 
progression of the swelling stops. Any tourniquet or constriction should be removed quickly if already Toxins 2010, 2 
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placed as first aid. This is not recommended in Martinique, where immediately available anti-venom 
should be initiated in the emergency room if required. 
Management in the emergency department includes initial non-specific supportive measures. 
Usually, victims require adequate intravenous hydration to correct hypotension and electrolyte 
disorders. Tracheal intubation and mechanical ventilation are mandatory in case of coma, severe 
collapse, cardiac arrhythmia, or respiratory distress. Shock is treated with fluids, followed by 
vasopressors to improve haemodynamic function or inotropic drugs to counteract conduction 
disturbances. However, such life-threatening presentations remain exceptional with B. lanceolatus 
envenomation. Analgesics and tetanus prophylaxis are systematic. In addition, grade 3 and 4 victims 
should receive empiric antibiotics, as more than one-third of these patients present with a primary 
bacterial infection [5,18,22]. A suggested association of cefotaxime, gentamycine, and metronidazole 
appears adapted to the bacteria found in the snake oral cavity, including A. hydrophila, M. morganii, P. 
vulgaris, and Clostridium sp. [5]. Prophylactic antibiotics may also be discussed in the other patients, 
according to the rapidity of local envenoming signs, due to the high risk of wound infection. In 
contrast, systematic administration of corticosteroids, histamine H1- and H2-receptor blockers, and 
heparin has not been evidenced [5]. All B. lanceolatus victims should be admitted, either to the 
emergency department for continuous and close observation for a minimum of 24h before discharge or 
to the intensive care unit if treated with antivenom. 
6. Antivenom Therapy 
The most important variable affecting the severity and outcome of envenoming from most viperid 
and crotalid snakes is the time elapsed between the bite and treatment initiation with a specific 
antivenom [2]. Usually, when considering any antivenom in snake-bites, the risk of adverse reactions 
must be weighed against the benefits of reducing venom toxicity. A purified monospecific antivenom 
serum for B. lanceolatus toxin neutralization is available since 1993 in Martinique [5,14].Bothrofav
® is 
manufactured by Sanofi-Pasteur, Lyon, France. It has been obtained from horses hyperimmunized with 
B. lanceolatus venoms. It contains 97% antivenom F(ab)2 (bivalent antigen-binding fragment) and 3% 
antivenom Fab (antigen-binding fragment). Alternatives (e.g., different other types of antivenom) 
should be considered as well if available. 
Initial strategy was to reserve antivenom for the most severe cases and use anticoagulants to prevent 
thromboses in all other patients. However, this approach was modified after the observation of serious 
thromboses in patients with moderate poisoning [5]. A prospective study assessed that administration 
within 6 h of the bite is the only effective treatment in preventing severe thromboses, when compared 
with death or major sequelae in 25% of untreated patients [22]. Moreover, it was shown to 
significantly reduce the length of hospital treatment. General recommendations for the management of 
crotalid envenomations proposed in 1983 by Reid & Theakston [26] are valid for B. lanceolatus [25]. 
Because clinical indicators of severity are often associated with high serum levels of venom, specific 
antivenom serotherapy is recommended to always be given to the cases of envenoming determined to 
be the most serious on clinical grounds. The presence of such indicators in the course of crotalid 
envenomation, even if labelled as “moderate” calls for immediate treatment with an appropriate 
minimum dose of specific antivenom, without waiting for signs of more severe envenomation.  Toxins 2010, 2 
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Antivenom administration is indicated in case of progressive signs of envenomation or imminent 
risk of acute complication. Ideally, it should be intravenously infused less than 30 min after hospital 
admission: its effectiveness is a function of how rapidly it is administrated [18,27]. It remains efficient 
even 4 to 5 days after the biting. Its dose regimen should be adapted to the envenomation severity, e.g., 
to the development of oedema and pain intensity (grade 2 to 4, Table 1). In bitten children, the regimen 
is unchanged whatever their weight is but may require continuous infusion using electrical syringe to 
limit the infused volume. This clinical attitude is based on the postulate established with pit viper bites, 
that signs are a reflection of the amount of venom injected [4]. The recommended doses were recently 
increased in comparison to those in the 90s, to be at least 40 to 80 mL, intravenously delivered at  
10–20 mL per hour infusion rate (Table 1) [19]. Treatment duration is approximately 2–8 hours, till 
control of envenomation syndrome is achieved. As grading envenomation is a dynamic process, 
additional doses should be administered, based on the patient's clinical course (e.g., for recurrent 
progressive swelling or coagulopathy).  
In a recent study, among a total of thirty-three patients who did not receive antivenom serum or 
who received it eight hours after being bitten, fourteen (42%) developed severe thrombotic 
complications such as cerebral infarctions, myocardial infarctus, myocardial and cerebral infarctions 
and pulmonary embolisms [5,18]. Four of the fourteen patients who were not treated with the 
antivenom, died. Interestingly, in seventy patients who received the antivenom within 6 hours of being 
bitten, no thrombotic complications were observed. Thus, antivenom serum has to be given in the first 
six hours prior to the bite, as a key for success. However, despite this strategy, three patients bitten by 
B. lanceolatus were recently reported to have developed cerebral infarctions [19]. These 3 patients 
received the antivenom within the required time. Several causes were suggested to explain the 
treatment failure, including variability in the venom composition or loss of activity of the antibodies 
produced, in the 90s.  
Researchers are now working to identify the main causes for treatment failure. Sanofi-Pasteur 
announced a reduction of the antivenom power of their marketed serum up to 20-fold the lethal dose 
50% per millilitre. To our opinion, all B. lanceolatus venom antigens may have not been represented in 
the initial venom pool which was derived from only 7 snakes used to immunise horses for antivenom 
production. The World Health Organisation currently recommends a pool from at least 50 snakes of 
each species to obtain a reliable antivenomen serum [28]. Thus, antivenom serum should be   
re-improved while probably including activity against Bothrops caribbaeus which shares a 
monophyletic group with B. lanceolatus and whose venom produces a similar thrombotic syndrome 
[16]. However, the manufacture of such an antivenom represents a great challenge for the future. 
Early intravenous infusion of antivenom serum is well-tolerated [22]. Undesirable reactions may 
occur with this equine antivenom, including immediate anaphylactic reactions, anaphylactoid reactions 
(like vomiting, rash, pruritus, and bronchospasm), and serum sickness responding to steroids. 
However, their incidence is rare and their severity mild. If the side-effect is not life-threatening, 
antivenom serum infusion should be first interrupted and then reintroduced up to the initially advised 
dose. Thus, as Bothrofav
® appears safe and well-tolerated, it should be indicated even if the 
envenomation is moderate. Moreover, it may be considered as a preventative measure even if any 
signs of envenomation exist. Waiting for the envenomation to get worse is not recommended as 
permanent injury could result. Toxins 2010, 2 
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7. Conclusions 
Bothrops lanceolatus, notoriously named “Fer-de-Lance”, is the only endemic snake in Martinique. 
It is responsible of about 20–30 declared bites per year. Envenomation generally leads to swelling and 
pain, while occasionally, systemic signs and/or coagulopathy may appear. Severe multifocal vascular 
thromboses may result in life-threatening symptoms leading to permanent disabilities or death. An 
equine monovalent antivenom serum (Bothrofav
®) was shown to be safe and effective for the 
treatment of B. lanceolatus bites when used within 6 hours. However, in recent cases, thrombotic 
stroke occurred despite antivenom early administration, questioning the necessity to obtain an 
improved antivenom. 
References 
1.  McDiarmid, R.W.; Campbell, J.A.; Touré, T. In Snake Species of the World: A Taxonomic and 
Geographic Reference, 1st Ed.; Herpetologists' League: Washington, D.C., USA, 1999;   
Volume 1, pp. 1–511.  
2.  Warrell, D.A. Snakebites in Central and South America: Epidemiology, clinical features, and 
clinical management. Bothrops lancelatus. In The Venomous Reptiles of the Western Hemisphere; 
Campbell, J.A., Lamar W.W., Eds.; Cornell University Press: New York, USA, 2004;   
pp. 743–744. 
3.  Wüster, W.; Thorpe, R.S.; Salomão, M.D.G.; Thomas, L.; Puorto, G.; Theakston, R.D.G.; 
Warrell, D.A. Origin and phylogenic position of the Lesser Antillean species of Bothrops 
(Serpentes Viperidae): Biogeographic and medicals implications. Bull. Nat. Hist. Mus. Lond. 
(Zool.) 2002, 68, 101–106. 
4.  Gold, B.S.; Dart, R.C.; Barish, R.C. Bites of venomous Snakes. N. Engl. J. Med.2002,  347,  
347–356. 
5.  Thomas, L.; Tyburn, B.; Bucher, B.; Pecout, F.; Ketterlé, J.; Rieux, D.; Smadja, D.; Garnier, D.; 
Plumelle, Y. Prevention of thromboses in human patients with Bothrops lanceolatus envenoming 
in Martinique: Failure of anticoagulants and efficacy of a monospecific antivenom. Am. J. Trop. 
Med. Hyg. 1995, 52, 419–426. 
6.  Gutiérrez, J.M.; Rucavado, A. Snake venom metalloproteinases: Their role in the pathogenesis of 
local tissue damage. Biochimie 2000, 82, 841–845. 
7.  Gutiérrez, J.M.; Sanz, L.; Escolano, J.; Fernández, J.; Lomonte, B.; Angulo, Y.; Rucavado, A.; 
Warrell, D.A.; Calvete, J.J. Snake venomics of the Lesser Antillean pit vipers Bothrops 
caribbaeus and Bothrops lanceolatus: Correlation with toxicological activities and 
immunoreactivity of a heterologous antivenom. J. Proteome Res.2008, 7, 4396–4408. 
8.  Lôbo de Araújo, A.; Kamiguti, A.; Bon, C. Coagulant and anticoagulant activities of Bothrops 
lanceolatus (Fer de lance) venom. Toxicon 2001, 39, 371–375. 
9.  Lôbo de Araújo, A.; Donato, J.L.; Bon, C. Purification from Bothrops lanceolatus (Fer de lance) 
venom of a fibrino(geno)lytic enzyme with esterolytic activity. Toxicon 1998, 36, 745–758. 
10.  Faria, L.; Antunes, E.; Bon, C.; Lôbo de Araújo, A. Pharmacological characterization of the rat 
paw edema induced by Bothrops lanceolatus (Fer de lance) venom. Toxicon 2001, 39, 825–830. Toxins 2010, 2 
 
172
11. Terra, R.M.; Pinto, A.F.; Guimarães, J.A.; Fox, J.W. Proteomic profiling of snake venom 
metalloproteinases (SVMPs): Insights into venom induced pathology. Toxicon 2009, 6, 836–844. 
12.  de Araújo, A.L.; Radvanyi, F.; Bon, C. Purification of an acidic phospholipase A2 from Bothrops 
lanceolatus (fer de lance) venom: Molecular and enzymatic properties. Toxicon  1994,  32,  
1069–1081. 
13.  Guimarães, A.Q.; Cruz–Höfling, M.A.; Ferreira de Araújo, P.M.; Bon, C.; Lôbo de Araújo, A. 
Pharmacological and histopathological characterization of Bothrops lanceolatus (Fer de lance) 
venom-induced edema. Inflamm. Res. 2004, 53, 284–291. 
14.  Bogarin, G.; Romero, M.; Rojas, G.; Lutsch, C.; Casadamont, M.; Lang, J.; Otero, R.; Gutiérrez, 
J.M. Neutralization, by a monospecific Bothrops lanceolatus antivenom, of toxic activities 
induced by homologous and heterologous Bothrops snake venoms. Toxicon 1999, 37, 551–557. 
15.  Stroka, A.; Donato, J.L.; Bon, C.; Hyslop, S.; de Araújo, A.L. Purification and characterization of 
a hemorrhagic metalloproteinase from Bothrops lanceolatus (Fer-de-lance) snake venom. Toxicon 
2005, 45, 411–420. 
16.  Numeric, P.; Moravie, V.; Didier, M.; Chatot-Henry, D.; Cirille, S.; Bucher, B.; Thomas, L. 
Multiple cerebral infarctions following a snakebite by Bothrops caribbaeus. Am. J. Trop. Med. 
Hyg. 2002, 67, 287–288. 
17.  Gold, B.S.; Barish, R.A. Venomous snakebites. Current concepts in diagnosis, treatment, and 
management. Emerg. Med. Clin. North Am. 1992, 10, 249–267. 
18.  Thomas, L.; Tyburn, B.; Ketterlé, J.; Biao, T.; Mehdaoui, H.; Moravie, V.; Rouvel, C.; Plumelle, 
Y.; Bucher, B.; Canonge, D.; Marie-Nelly, C.A.; Lang, J. Prognostic significance of clinical 
grading of patients envenomed by Bothrops lanceolatus in Martinique. Trans. R. Soc. Trop. Med. 
Hyg. 1998, 92, 542–545. 
19.  Thomas, L.; Chausson, N.; Uzan, J.; Kaidomar, S.; Vignes, R.; Plumelle, Y.; Bucher, B.; Smadja, 
D. Thrombotic stroke following snake bites by the “fer-de-Lance” Bothrops lanceolatus in 
Martinique despite antivenom treatment: A report of three recent cases. Toxicon 2006, 48, 23–28. 
20.  Merle, H.; Donnio, A.; Ayeboua, L.; Plumelle, Y.; Smadja, D.; Thomas, L. Occipital infarction 
revealed by quadranopsia following snakebite by Bothrops lanceolatus. Am. J. Trop. Med. Hyg. 
2005, 73, 583–585. 
21. Mosquera, A.; Idrovo, L.A.; del Brutto, O.H. Stroke following Bothrops spp. snakebite. 
Neurology 2003, 60, 1577–1580. 
22.  Thomas, L.; Tyburn, B.; Lang, J.; Ketterle, J. Early infusion of a purified monospecific F(ab')2 
antivenom serum for Bothrops lanceolatus bites in Martinique. Lancet 1996, 347, 406. 
23.  Estrade, G.; Garnier, D.; Bernasconi, F.; Donatien, Y. Pulmonary embolism and disseminated 
intravascular coagulation after being bitten by a Bothrops lanceolatus snake. Apropos of a case. 
Arch. Mal. Coeur Vaiss.1989, 82, 1903–1905. 
24. Malbranque, S.; Piercecchi-Marti, M.D.; Thomas, L.; Barbey, C.; Courcier, D.; Bucher, B.; 
Ridarch, A.; Smadja, D.; Warrell, D.A. Fatal diffuse thrombotic microangiopathy after a bite by 
the "Fer-de-Lance" pit viper (Bothrops lanceolatus) of Martinique. Am. J. Trop. Med. Hyg. 2008, 
78, 856–861. Toxins 2010, 2 
 
173
25.  Bucher, B.; Canonge, D.; Thomas, L.; Tyburn, B.; Robbe-Vincent, A.; Choumet, V.; Bon, C.; 
Ketterlé, J.; Lang, J. Clinical indicators of envenoming and serum levels of venom antigens in 
patients bitten by Bothrops lanceolatus in Martinique. Trans. R. Soc. Trop. Med. Hyg. 1997, 91,  
186–190. 
26.  Reid, H.A.; Theakston, R.D.G. The management of snake bite. Bull. World Health Organ. 1983, 
61, 885–895. 
27. Thomas, L.; Tyburn, B.; Lang, J.; Biao, T.; Moravie, V.; Rouvel, C.; Numeric, P. Snake 
(Bothrops lanceolatus) F(ab)2 antivenom (equine) use in Martinique: Safety and efficacy. Réan. 
Urg. 1998, 7, 381–387. 
28. Theakston, R.D.G.; Warrell, D.A.; Griffiths, E. Report on a WHO workshop on the 
standardization and control of antivenoms. Toxicon 2003, 41, 541–557. 
© 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. 
This article is an open-access article distributed under the terms and conditions of the Creative 
Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). 